Research map: Advances in the treatment of systemic lupus erythematosus: Biologicals, small‐molecular agents, and cell‐depleting therapies coming to the clinic

Back to the article

Papers in this map

  1. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial · Sandra Navarra · 2011 · 2099 citations · Cited by this paper
  2. The relationship between autoantibody and complement levels in the sera of patients with systemic lupus erythematosus · David S. Pisetsky · 2026 · Cites this paper
  3. Acute clinical events and trajectories of frailty after age 60: A population‐based cohort study · 2026 · Related
  4. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus · Richard Alan Furie · 2011 · 1694 citations · Cited by this paper
  5. Blood biomarkers of Alzheimer's disease and 15‐year decline in cognitive and motor functions in older adults · 2026 · Related
  6. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study · Brad H. Rovin · 2012 · 1471 citations · Cited by this paper
  7. Anti‐inflammatory agents in atherosclerosis—and a need for reform: Extraordinary claims require extraordinary evidence · 2026 · Related
  8. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial · Catriona Grigor · 2004 · 1439 citations · Cited by this paper
  9. Perioperative immune checkpoint inhibitor therapy across tumors: Insights and shared lessons from a rapidly evolving field · 2026 · Related
  10. Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial · Joan T. Merrill · 2009 · 1419 citations · Cited by this paper
  11. Fecal microbiota transplantation‐based treatment protocol for chronic insomnia disorder: A randomized, double‐blind, placebo‐controlled trial · 2026 · Related
  12. Trial of Anifrolumab in Active Systemic Lupus Erythematosus · Eric Francis Morand · 2019 · 1387 citations · Cited by this paper
  13. Epigenetic analyses suggest different pathways during pregnancy for development of type 1 diabetes in children with high versus low‐neutral human leukocyte antigen‐risk · 2026 · Related
  14. Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis · Ellen M. Ginzler · 2005 · 1133 citations · Cited by this paper
  15. Collagen and microvascular alterations contribute to neuromuscular degeneration and disease progression in chronic intestinal pseudo‐obstruction · 2026 · Related
  16. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus · Andréas Mackensen · 2022 · 1101 citations · Cited by this paper
  17. Old and new autoantibodies in systemic lupus erythematosus · 2026 · Related
  18. CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up · Fabian Müller · 2024 · 1085 citations · Cited by this paper
  19. Induction treatment of lupus nephritis: to pulse or not to pulse? Whether ’tis nobler to universally or selectively prescribe · 2025 · Related
  20. Immunosuppressive therapy in lupus nephritis: The Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamide · Frédéric Houssiau · 2002 · 1080 citations · Cited by this paper
  21. Low-dose IL-2 therapy in autoimmune diseases: An update review · 2023 · Related
  22. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update · Antonis Fanouriakis · 2023 · 1063 citations · Cited by this paper
  23. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis · Richard Alan Furie · 2020 · 1036 citations · Cited by this paper
  24. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis · Dimitrios T. Boumpas · 1992 · 829 citations · Cited by this paper
  25. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force · Ronald van Vollenhoven · 2014 · 743 citations · Cited by this paper
  26. Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis · Mary Anne Dooley · 2011 · 646 citations · Cited by this paper
  27. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial · Brad H. Rovin · 2021 · 629 citations · Cited by this paper
  28. Immunopathogenic mechanisms of systemic autoimmune disease · Marie Wahren‐Herlenius · 2013 · 597 citations · Cited by this paper
  29. Novel paradigms in systemic lupus erythematosus · Thomas Dörner · 2019 · 581 citations · Cited by this paper
  30. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) · Graciela S. Alarcón · 2007 · 538 citations · Cited by this paper
  31. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial · Richard Alan Furie · 2019 · 512 citations · Cited by this paper
  32. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial · Laura C. Coates · 2015 · 478 citations · Cited by this paper
  33. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response · Ronald van Vollenhoven · 2012 · 415 citations · Cited by this paper
  34. Systemic lupus erythematosus · Alberta Yik-Bun Hoi · 2024 · 394 citations · Cited by this paper
  35. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165 · Stephen T. Wrobleski · 2019 · 389 citations · Cited by this paper
  36. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual · Barri J. Fessler · 2005 · 387 citations · Cited by this paper
  37. 2021 DORIS definition of remission in SLE: final recommendations from an international task force · Ronald van Vollenhoven · 2021 · 378 citations · Cited by this paper
  38. Interferon pathway in SLE: one key to unlocking the mystery of the disease · Lars Rönnblom · 2019 · 369 citations · Cited by this paper
  39. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial · Jing He · 2019 · 351 citations · Cited by this paper

Source: OpenAlex (CC0)